NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced cord blood-derived natural killer cells
A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) transduced with a retroviral vector expressing interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domains of CD28 and to the zeta chain of the TCR/CD3 complex (CD3-zeta), and is linked to the suicide gene inducible caspase 9 (iCasp9; iC9), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced CB-NKs recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered NK cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9, and results in apoptosis of the administered NK cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. IL-15 enhances the cytotoxic effect of the NK cells. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:allogeneic iC9/CAR19/IL15-transduced CB-NK cells
CAR-CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells
iC9/CAR19/IL15-transduced CB-NKs
iC9/CAR-CD19-CD28-zeta-2A/IL-15 CB-NK cells
UCB-derived CAR-CD19-CD28-zeta-2A-iCasp9-IL15 engineered NK cells